Trends in Kidney Transplantation over the Past Decade, Drugs, vol.22, issue.5, pp.3-10, 2008. ,
DOI : 10.2165/00003495-200868001-00002
Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF), Clin Transplant, vol.10, issue.1 2, pp.77-84, 1996. ,
Clinical Pharmacokinetics of Mycophenolate Mofetil, Clinical Pharmacokinetics, vol.34, issue.6, pp.429-55, 1998. ,
DOI : 10.2165/00003088-199834060-00002
Therapeutic drug monitoring for mycophenolic acid in patients with autoimmune diseases, Nephrology Dialysis Transplantation, vol.23, issue.11, pp.3386-3394, 2008. ,
DOI : 10.1093/ndt/gfn497
Individualized Mycophenolate Mofetil Dosing Based on Drug Exposure Significantly Improves Patient Outcomes After Renal Transplantation, American Journal of Transplantation, vol.82, issue.1, pp.2496-503, 2007. ,
DOI : 10.1097/00007691-200412000-00005
Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled Trial, Transplantation, vol.86, issue.8, pp.1043-51, 2008. ,
DOI : 10.1097/TP.0b013e318186f98a
Current Issues in Therapeutic Drug Monitoring of Mycophenolic Acid: Report of a Roundtable Discussion, Therapeutic Drug Monitoring, vol.23, issue.4, pp.305-320, 2001. ,
DOI : 10.1097/00007691-200108000-00001
Maximum A Posteriori Bayesian Estimation of Mycophenolic Acid Pharmacokinetics in Renal Transplant Recipients at Different Postgrafting Periods, Therapeutic Drug Monitoring, vol.27, issue.3, pp.354-61, 2005. ,
DOI : 10.1097/01.ftd.0000162231.90811.38
Population Pharmacokinetics and Bayesian Estimation of Mycophenolic Acid Concentrations in Stable Renal Transplant Patients, Clinical Pharmacokinetics, vol.20, issue.6, pp.253-66, 2004. ,
DOI : 10.2165/00003088-200443040-00004
Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth Official Adult Lung and Heart???Lung Transplantation Report???2007, The Journal of Heart and Lung Transplantation, vol.26, issue.8, pp.782-95, 2007. ,
DOI : 10.1016/j.healun.2007.06.003
Immunosuppressive therapy after human lung transplantation, European Respiratory Journal, vol.23, issue.1, pp.159-71, 2004. ,
DOI : 10.1183/09031936.03.00039203
Immunosuppression for Lung Transplantation, Drugs, vol.22, issue.11, pp.1531-1540, 2007. ,
DOI : 10.2165/00003495-200767110-00002
Monitoring C2 Level Predicts Exposure in Maintenance Lung Transplant Patients Receiving the Microemulsion Formulation of Cyclosporine (Neoral), The Journal of Heart and Lung Transplantation, vol.24, issue.8, pp.1076-80, 2005. ,
DOI : 10.1016/j.healun.2003.05.002
Pharmacokinetics of mycophenolic acid associated with calcineurin inhibitors: long-term monitoring in stable lung recipients with and without cystic fibrosis, The Journal of Heart and Lung Transplantation, vol.22, issue.5, pp.587-90, 2003. ,
DOI : 10.1016/S1053-2498(02)01159-2
Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients, Journal of Pharmacokinetics and Pharmacodynamics, vol.84, issue.3, pp.541-64, 2009. ,
DOI : 10.1007/s10928-009-9136-6
Pharmacokinetic Optimization of Immunosuppressive Therapy in Thoracic Transplantation: Part II, Clinical Pharmacokinetics, vol.59, issue.3, pp.489-516, 2009. ,
DOI : 10.2165/11317240-000000000-00000
Limited Sampling Strategy for Predicting Area Under the Concentration-Time Curve of Mycophenolic Acid in Adult Lung Transplant Recipients, Pharmacotherapy, vol.19, issue.9, pp.1232-1272, 2006. ,
DOI : 10.2165/00003088-200241050-00001
Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome?, Expert Opinion on Drug Metabolism & Toxicology, vol.82, issue.2, pp.251-61, 2007. ,
DOI : 10.1097/01.ftd.0000179848.65266.aa
Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategy, European Journal of Clinical Pharmacology, vol.57, issue.11, pp.805-816, 2002. ,
DOI : 10.1007/s00228-001-0389-2
A Double Absorption-Phase Model Adequately Describes Mycophenolic Acid Plasma Profiles in De Novo Renal Transplant Recipients Given Oral Mycophenolate Mofetil, Clinical Pharmacokinetics, vol.23, issue.6, pp.837-884, 2005. ,
DOI : 10.2165/00003088-200544080-00005
, Mycophenolate Mofetil and a 6-Month Course of Steroids, American Journal of Transplantation, vol.6, issue.2, pp.2522-2553, 2007. ,
DOI : 10.1128/JVI.75.13.6022-6032.2001
Tacrolimus Population Pharmacokinetic-Pharmacogenetic Analysis and Bayesian Estimation in Renal Transplant Recipients, Clinical Pharmacokinetics, vol.76, issue.8, pp.805-821, 2009. ,
DOI : 10.2165/11318080-000000000-00000
URL : https://hal.archives-ouvertes.fr/hal-01390737
Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients, Pharmacogenetics and Genomics, vol.17, issue.5, pp.321-351, 2007. ,
DOI : 10.1097/FPC.0b013e32801430f8
Sirolimus Population Pharmacokinetic/Pharmacogenetic Analysis and Bayesian Modelling in Kidney Transplant Recipients, Clinical Pharmacokinetics, vol.44, issue.11, pp.1135-1183, 2006. ,
DOI : 10.2165/00003088-200645110-00007
202 New Tools for Mycophenolate Mofetil (MMF) Dose Optimization in Lung Transplant Recipients during the First Year Post-Transplantation: The STIMMUGREP Trial, The Journal of Heart and Lung Transplantation, vol.30, issue.4, p.74, 2011. ,
DOI : 10.1016/j.healun.2011.01.209
Determination of Mycophenolic Acid Plasma Levels in Renal Transplant Recipients Co-administered Sirolimus: Comparison of an Enzyme Multiplied Immunoassay Technique (EMIT) and Liquid Chromatography???Tandem Mass Spectrometry, Therapeutic Drug Monitoring, vol.28, issue.2, pp.274-281, 2006. ,
DOI : 10.1097/01.ftd.0000197092.84935.ef
Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis, AAPS PharmSci, vol.4, issue.4, p.27, 2002. ,
DOI : 10.1208/ps040427
Model Appropriateness and Population Pharmacokinetic Modeling, The Journal of Clinical Pharmacology, vol.43, issue.6, pp.610-633, 2003. ,
DOI : 10.1177/0091270003253624
A new equivalence based metric for predictive check to qualify mixed-effects models, The AAPS Journal, vol.7, issue.3, pp.523-554, 2005. ,
DOI : 10.1208/aapsj070353
Population Pharmacokinetic Modeling of Oral Cyclosporin Using NONMEM, Therapeutic Drug Monitoring, vol.26, issue.1, pp.23-30, 2004. ,
DOI : 10.1097/00007691-200402000-00006
Evaluation of Mixture Modeling with Count Data Using NONMEM, Journal of Pharmacokinetics and Pharmacodynamics, vol.30, issue.3, pp.167-83, 2003. ,
DOI : 10.1023/A:1025564409649
Population Pharmacokinetics of Mycophenolic Acid, Clinical Pharmacokinetics, vol.27, issue.3, pp.827-865, 2008. ,
DOI : 10.2165/0003088-200847120-00007
Design and power of a population pharmacokinetic study, Pharmaceutical Research, vol.18, issue.1, pp.75-82, 2001. ,
DOI : 10.1023/A:1011030827847
Limited Sampling Models and Bayesian Estimation for Mycophenolic Acid Area under the Curve Prediction in Stable Renal Transplant Patients Co-Medicated with Ciclosporin or Sirolimus, Clinical Pharmacokinetics, vol.7, issue.11, pp.745-58, 2009. ,
DOI : 10.2165/11318060-000000000-00000
Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil, British Journal of Clinical Pharmacology, vol.22, issue.2, pp.188-97, 2003. ,
DOI : 10.1046/j.1365-2125.2003.01863.x
Population Pharmacokinetics of Mycophenolic Acid in Renal Transplant Recipients, Clinical Pharmacokinetics, vol.43, issue.6, pp.1083-96, 2005. ,
DOI : 10.2165/00003088-200544100-00006
Explaining Variability in Mycophenolic Acid Exposure to Optimize Mycophenolate Mofetil Dosing: A Population Pharmacokinetic Meta-Analysis of Mycophenolic Acid in Renal Transplant Recipients, Journal of the American Society of Nephrology, vol.17, issue.3, pp.871-80, 2006. ,
DOI : 10.1681/ASN.2005101070
Nonlinear Relationship between Mycophenolate Mofetil Dose and Mycophenolic Acid Exposure: Implications for Therapeutic Drug Monitoring, Clinical Journal of the American Society of Nephrology, vol.6, issue.3, pp.656-63, 2011. ,
DOI : 10.2215/CJN.05440610
The Evolution of Population Pharmacokinetic Models to Describe the Enterohepatic Recycling of Mycophenolic Acid in Solid Organ Transplantation and Autoimmune Disease, Clinical Pharmacokinetics, vol.11, issue.3-4, pp.1-24, 2011. ,
DOI : 10.2165/11536640-000000000-00000
Assessment of actual significance levels for covariate effects in NONMEM, Journal of Pharmacokinetics and Pharmacodynamics, vol.28, issue.3, pp.231-52, 2001. ,
DOI : 10.1023/A:1011527125570
Cyclosporine Interacts with Mycophenolic Acid by Inhibiting the Multidrug Resistance-Associated Protein 2, American Journal of Transplantation, vol.41, issue.1, pp.987-94, 2005. ,
DOI : 10.1046/j.1523-1755.2001.00782.x
The Role of Organic Anion???Transporting Polypeptides and Their Common Genetic Variants in Mycophenolic Acid Pharmacokinetics, Clinical Pharmacology & Therapeutics, vol.87, issue.1, pp.100-108, 2010. ,
DOI : 10.1086/379378
URL : https://hal.archives-ouvertes.fr/inserm-00415314
Pharmacokinetic Study of Tacrolimus in Cystic Fibrosis and Non-Cystic Fibrosis Lung Transplant Patients and Design of Bayesian Estimators Using Limited Sampling Strategies, Clinical Pharmacokinetics, vol.21, issue.4, pp.1317-1345, 2005. ,
DOI : 10.2165/00003088-200544120-00010
Pharmacokinetics of Mycophenolic Acid and its Phenolic-Glucuronide and Acyl Glucuronide Metabolites in Stable Thoracic Transplant Recipients, Therapeutic Drug Monitoring, vol.30, issue.3, pp.282-91, 2008. ,
DOI : 10.1097/FTD.0b013e318166eba0
Limited Sampling Strategies for Therapeutic Drug Monitoring of Mycophenolate Mofetil Therapy in Patients With Autoimmune Disease, Therapeutic Drug Monitoring, vol.31, issue.3, pp.382-90, 2009. ,
DOI : 10.1097/FTD.0b013e3181a23f1a